Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer

NCT01095120 is registered in ClinicalTrials.gov with Genta Incorporated as lead sponsor.

NCT NCT01095120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01095120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer
Lead sponsor
Genta Incorporated
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2010
Completion date
October 31, 2012
Enrollment
27 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of esophagogastric junction, adenocarcinoma of the stomach